Effect of zoledronic acid on oral fibroblasts and epithelial cells: A potential mechanism of bisphosphonate-associated osteonecrosis

British Journal of Haematology

Volumn 144, Issue 5, 2009, Pages 667-676

  Scheper, Mark A ^a,b,c   Badros, Ashraf ^a,c   Chaisuparat, Risa ^b   Cullen, Kevin J ^a,c   Meiller, Timothy F ^b,c  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b Dental School   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Apoptosis; Bisphosphonate; Epithelium; Fibroblasts; Zoledronic acid

Indexed keywords

CASPASE; CASPASE 3; CASPASE 9; DEATH RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN; PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE NECROSIS; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FIBROBLAST; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC CODE; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE;

APOPTOSIS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CASPASE 3; CASPASE 9; CELL LINE; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GINGIVA; HUMANS; IMIDAZOLES; IN SITU NICK-END LABELING; JAW DISEASES; MOUTH MUCOSA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECROSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 58849116790     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07504.x     Document Type: Article

References (31)

1. Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R. Meiller, T. (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology, 24, 945 952.
2. Bagan, J.V., Jimenez, Y., Murillo, J., Hernandez, S., Poveda, R., Sanchis, J.M., Diaz, J.M. Scully, C. (2006) Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncology, 42, 327 329.
3. Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L.A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., Terpos, E. Dimopoulos, M.A. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology, 23, 8580 8587.
4. Bilezikian, J.P. (2006) Osteonecrosis of the jaw - do bisphosphonates pose a risk? The New England Journal of Medicine, 355, 2278 2281.
5. Chen, T., Berenson, J., Vescio, R., Swift, R., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., Schran, H., Seaman, J. Skerjanec, A. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in patients with cancer and bone metastases. Journal of Clinical Pharmacology, 42, 1228 1236.
6. Civitelli, R., Napoli, N. Armamento-Villareal, R. (2007) Use of intravenous bisphosphonates in osteoporosis. Current Osteoporosis Reports, 5, 8 13.
7. Coxon, J.P., Oades, G.M., Kirby, R.S. Colston, K.W. (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU International, 94, 164 170.
8. Cremers, S.C., Pillai, G. Papapoulos, S.E. (2005) Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clinical Pharmacokinetics, 44, 551 570.
9. Dunford, J.E., Rogers, M.J., Ebetino, F.H., Phipps, R.J. Coxon, F.P. (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. Journal of Bone and Mineral Research, 21, 684 694.
10. Farrugia, M.C., Summerlin, D.J., Krowiak, E., Huntley, T., Freeman, S., Borrowdale, R. Tomich, C. (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. The Laryngoscope, 116, 115 120.
11. Fleisch, H. (2003) Bisphosphonates in osteoporosis. European Spine Journal, 12, 142S 146S.
12. Goffinet, M., Thoulouzan, M., Pradines, A., Lajoie-Mazenc, I., Weinbaum, C., Faye, J.C. Séronie-Vivien, S. (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer, 6, 60.
13. Graham, D.Y. (2002) What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Digestive Diseases and Sciences, 47, 1665 1678.
14. Herbozo, P.J., Briones, D.L., Ferres, A.J. Torrealba, R.L. (2007) Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 65, 1650 1654.
15. Jeffcoat, M. Watts, N.B. (2008) Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. General Dentistry, 56, 96 102.
16. Kanis, J.A. (1995) Bone and cancer: pathophysiology and treatment of metastases. Bone, 17, 101S 105S.
17. Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., Gagel, R.F., Gilsanz, V., Guise, T., Koka, S., McCauley, L.K., McGowan, J., McKee, M.D., Mohla, S., Pendrys, D.G., Raisz, L.G., Ruggiero, S.L., Shafer, D.M., Shum, L., Silverman, S.L., Van Poznak, C.H., Watts, N., Woo, S.B., Shane, E. American Society for Bone Mineral Research 2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22, 1479 1491.
18. Lanza, F.L. (2002) Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treatments in Endocrinology, 1, 37 43.
19. Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G. Rogers, M.J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research, 13, 581 589.
20. Mavrokokki, T., Cheng, A., Stein, B. Goss, A. (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Journal of Oral and Maxillofacial Surgery, 65, 415 423.
21. Mundy, G.R. (1987) Bone resorption and turnover in health and disease. Bone, 8, S9 S16.
22. Parfitt, J.R. Driman, D.K. (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Human Pathology, 38, 527 536.
23. Reid, I.R., Bolland, M.J. Grey, A.B. (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone, 41, 318 320.
24. Rogers, M.J., Watts, D.J. Russell, R.G. (1997) Overview of bisphosphonates. Cancer, 80, 1652 1660.
25. Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J. Frith, J.C. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 88, 2961 2978.
26. Sedghizadeh, P.P., Kumar, S.K., Gorur, A., Schaudinn, C., Shuler, C.F. Costerton, J.W. (2008) Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery, 66, 767 775.
27. Skerjanec, A., Berenson, J., Hsu, C., Major, P., Miller, Jr., W.H., Ravera, C., Schran, H., Seaman, J. Waldmeier, F. (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. Journal of Clinical Pharmacology, 43, 154 162.
28. Smith, M.R. (2003) Antitumor activity of bisphosphonates. Clinical Cancer Research, 9, 5433 5434.
29. Weitzman, R., Sauter, N., Eriksen, E.F., Tarassoff, P.G., Lacerna, L.V., Dias, R., Altmeyer, A., Csermak-Renner, K., McGrath, L., Lantwicki, L. Hohneker, J.A. (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Critical Reviews in Oncology Hematology, 62, 148 152.
30. Woo, S.B., Hellstein, J.W. Kalmar, J.R. (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144, 753 761.
31. Wynn, R.L., Meiller, T.F. Crossley, H.L. (2007) Drug Information Handbook for Dentistry, 13th edn. Lexi-Comp, Ohio, pp. 1685 1688.